Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P63165
UPID:
SUMO1_HUMAN
Alternative names:
GAP-modifying protein 1; SMT3 homolog 3; Sentrin; Ubiquitin-homology domain protein PIC1; Ubiquitin-like protein SMT3C; Ubiquitin-like protein UBL1
Alternative UPACC:
P63165; A8MUS8; B2R4I5; P55856; Q6FGG0; Q6NZ62; Q93068
Background:
Small ubiquitin-related modifier 1 (SUMO1) plays a pivotal role in various cellular processes, including nuclear transport, DNA replication, and signal transduction, through its post-translational modification of proteins. Known by alternative names such as Sentrin and Ubiquitin-like protein UBL1, SUMO1's ability to covalently attach to proteins influences cellular mechanisms critical for maintaining homeostasis and responding to stress.
Therapeutic significance:
SUMO1's involvement in Non-syndromic orofacial cleft 10, a birth defect characterized by cleft lips, highlights its potential as a therapeutic target. Understanding the role of SUMO1 could open doors to potential therapeutic strategies for managing and possibly preventing conditions associated with its dysfunction.